NCT03322267 2026-03-06
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
National Taiwan University Hospital
Phase 2 Completed
Clinical Trials
139 trialsNCT07363629 2026-01-23
Impact of Preserving Versus Ligating the Right Gastric Artery on Anastomotic Outcomes After McKeown Esophagectomy: A Randomized Controlled Trial
The First Hospital of Hebei Medical University
Phase NA Completed
NCT04045496 2025-12-29
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1 Completed
NCT06549816 2025-12-15
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Seagen Inc.
Phase 1 Completed
NCT07236320 2025-11-19
Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC
Sichuan Cancer Hospital and Research Institute
Phase NA Completed
NCT06192212 2025-10-02
PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive Esophagectomy
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Completed
NCT07201571 2025-10-01
A Retrospective Cohort Study of Patients Who Underwent Curative-intent Esophagectomy for ESCC at a Tertiary Referral Center in South Korea
Samsung Medical Center
Completed
NCT06333665 2025-09-30
PPIO-007 Correlation Analysis of Type II Diabetes Mellitus on Short-term and Long-term Outcomes of Patients With Esophageal Squamous Cell Cancer Undergoing Minimally Invasive Esophagectomy
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Completed
NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT07181850 2025-09-18
pCR-ESCC
Nanjing Medical University
Completed
NCT05880082 2025-08-24
PPIO-004-EC001
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT03708328 2025-08-20
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT03783442 2025-07-29
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT03797625 2025-07-23
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Fudan University
Phase 2 Completed
NCT04242199 2025-07-14
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT01351103 2025-06-13
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Novartis
Phase 1 Completed
NCT04548440 2025-06-12
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
Sun Yat-sen University
Phase 2 Completed
NCT03914443 2025-05-31
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
National Cancer Center, Japan
Phase 1 Completed
NCT04121286 2025-05-20
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Allist Pharmaceuticals, Inc.
Phase 1 Completed
NCT03957590 2025-05-02
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT04704154 2025-04-18
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
Phase 2 Completed
NCT04925284 2025-04-04
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
Phase 1 Completed
NCT04785820 2025-03-05
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Hoffmann-La Roche
Phase 2 Completed
NCT03937362 2025-03-03
preSINO
Shanghai Chest Hospital
Completed
NCT04732494 2025-01-31
AdvanTIG-203
BeiGene
Phase 2 Completed
NCT06775652 2025-01-15
ESCC
Sichuan Cancer Hospital and Research Institute
Phase 3 Completed
NCT05355168 2024-12-31
Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
Anhui Provincial Hospital
Phase 2 Completed
NCT02647125 2024-11-26
A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC
Fudan University
Phase 2 Completed
NCT02844075 2024-11-15
Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)
Yonsei University
Phase 2 Completed
NCT06691503 2024-11-15
A Clinical Trial of Esophagectomy for Esophageal Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT03985046 2024-11-07
Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC
Fudan University
Phase 2 Completed
NCT03430843 2024-10-26
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT03469557 2024-10-23
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
BeiGene
Phase 2 Completed
NCT04713891 2024-09-24
A Study of KF-0210 in Advanced Solid Tumors Patients
Keythera (Suzhou) Pharmaceuticals Co. Ltd
Phase 1 Completed
NCT04721223 2024-09-19
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT06063941 2024-08-27
High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy
Xijing Hospital of Digestive Diseases
Phase NA Completed
NCT04839471 2024-07-08
BEAR
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT04641871 2024-06-26
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03339843 2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2 Completed
NCT02830594 2024-02-20
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Completed
NCT06190652 2024-02-05
REICRAE
Tianjin Medical University Cancer Institute and Hospital
Completed
NCT06241066 2024-02-05
The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Completed
NCT06241079 2024-02-05
Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Completed
NCT04568200 2024-01-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT06184841 2023-12-28
HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma
Peking University Cancer Hospital & Institute
Phase 1 Completed
NCT02916511 2023-12-22
ESO-Shanghai9
Fudan University
Phase 2 Completed
NCT06165094 2023-12-11
ECPLNMvsSLNM
Sichuan Cancer Hospital and Research Institute
Completed
NCT04187352 2023-11-24
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
CStone Pharmaceuticals
Phase 3 Completed
NCT03792347 2023-11-22
PALACE-1
Ruijin Hospital
Phase 1 Completed